Recently, Mabwell Bioscience, a Chinese innovative biopharmaceutical company, announced a strategic collaboration with U.S.-based biotech firm Sentonix. Under the agreement, the two parties will engage in deep cooperation on the development of novel antibody therapeutics, with a primary focus on immuno-oncology. Mabwell will leverage its strengths in antibody discovery and engineering platforms, while Sentonix will contribute its expertise in target validation and preclinical research to jointly advance multiple drug candidates.This partnership marks another step in Mabwell’s global R&D expansion, accelerating the translation of innovative therapies from lab to clinic. As a company committed to developing high-quality, accessible biologics, Mabwell has been actively strengthening international collaborations, establishing R&D partnerships across multiple countries and regions. Sentonix, known for its proprietary target screening platform and translational medicine capabilities, is expected to bring complementary strengths to this alliance, potentially delivering breakthrough treatment options for patients.Industry experts note that the collaboration not only helps mitigate risks in drug development but also enhances both companies’ competitiveness in the global biopharmaceutical market. As joint programs progress, the two companies may further expand their synergies into additional therapeutic areas, driving innovation in the global biopharma industry.
近日，中国创新型生物制药企业迈威生物（Mabwell Bioscience）宣布与美国生物技术公司Sentonix达成战略合作。根据协议，双方将围绕新型抗体药物的开发展开深度合作，重点聚焦于肿瘤免疫治疗领域。迈威生物将利用其在抗体发现与工程化平台方面的技术优势，结合Sentonix在靶点验证及临床前研究方面的专长，共同推进多个候选药物的研发进程。此次合作标志着迈威生物进一步拓展其全球化研发布局，加速创新疗法从实验室走向临床。作为一家致力于开发高质量、可及性生物药的企业，迈威生物近年来持续加强国际合作，已在全球多个国家和地区建立研发合作关系。而Sentonix则以其独特的靶点筛选平台和转化医学能力著称，此次联手有望为患者带来更具突破性的治疗选择。业内专家指出，该合作不仅有助于降低新药研发风险，还将提升双方在国际生物医药市场的竞争力。未来，随着合作项目的推进，双方或将在更多治疗领域展开协同创新，推动全球生物制药产业的发展。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/9891.html